Cassava Sciences Inc reports results for the quarter ended in December - Earnings Summary

Filana Therapeutics

28/02/2024 16:40

* Cassava Sciences Inc  SAVA.OQ  reported a quarterly
adjusted
loss of 50 cents​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of -47 cents.  The mean expectation of two analysts for the
quarter was for a loss of 52 cents per share. Wall Street
expected results to range from -64 cents to -40 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cassava Sciences Inc's reported EPS for the quarter was a
loss
of 50 cents​.
    * The company reported a quarterly loss of $20.92 million.
    * Cassava Sciences Inc shares had risen by 2.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cassava Sciences
Inc is $99.50 
This summary was machine generated from LSEG data February 28 at
04:39 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.52          -0.50          Beat
 Sep. 30 2023      -0.77          -0.61          Beat
 Jun. 30 2023      -0.59          -0.63          Missed
 Mar. 31 2023      -0.55          -0.58          Missed